• Home
  • Multiple Myeloma

Multiple Myeloma Treatment in China

NMPA-approved BCMA CAR-T, autologous stem cell transplant, and novel therapies at China’s top hematology centers

What Is Multiple Myeloma?

Multiple myeloma is a cancer of plasma cells — a type of white blood cell made in the bone marrow. In multiple myeloma, abnormal plasma cells multiply uncontrollably, crowding out healthy blood cells and producing abnormal proteins (M-proteins) that can damage kidneys, bones, and the immune system.

While multiple myeloma is considered treatable, it is generally incurable with standard therapy. However, recent advances — including BCMA-directed CAR-T cell therapy — have dramatically improved outcomes for patients with relapsed or refractory disease.

Common Signs & Symptoms

• Bone pain (back, ribs)
• Fatigue & weakness (anemia)
• Recurrent infections
• Kidney problems
• Elevated calcium levels
• Unexplained weight loss

Treatment Options in China

From NMPA-approved cellular therapy to established transplant protocols, China's top hematology centers offer a full range of myeloma treatments.

BCMA-Directed CAR-T Therapy

NMPA-approved BCMA-targeted CAR-T for relapsed/refractory myeloma, including cilta-cel (Carvykti equivalent) and domestic products. Genetically reprograms your T cells to kill BCMA-expressing myeloma cells.

Eligibility: ≥3 prior lines (PI + IMiD + anti-CD38)
Cost: USD 100K–250K (approved) / trial may waive drug cost
Learn more →

Autologous Stem Cell Transplant (ASCT)

High-dose chemotherapy followed by infusion of the patient's own stem cells. Standard of care for eligible newly diagnosed patients. China's centers have extensive transplant experience.

Centers: Shanghai Ruijin, CAMS Tianjin, PKU Cancer
Timeline: ~3–4 weeks in-hospital
Learn more →

Novel Agent Combinations

Proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory drugs (lenalidomide, pomalidomide), anti-CD38 antibodies (daratumumab, isatuximab), and newer agents including selinexor.

Use: Frontline, maintenance, and relapse settings
Advantage: Often available at lower cost than Western markets

Clinical Trials

China has one of the world's largest myeloma trial pipelines, including dual-target CAR-T (BCMA/GPRC5D), next-gen immunotherapies, and novel combinations. Some trials accept international patients.

Cost: Investigational drug may be free
Note: Strict eligibility; travel not covered
Check trial eligibility →

Why Choose China for Multiple Myeloma Treatment?

NMPA-Approved BCMA CAR-T

China was among the first countries to approve BCMA CAR-T, with real-world data from thousands of patients.

World-Class Hematology Centers

Shanghai Ruijin, CAMS Tianjin, and PKU Cancer Hospital have dedicated myeloma teams with extensive CAR-T experience.

Transparent Pricing

Approved therapy at 40–60% less than US list prices, with clear breakdowns across commercial, trial, and supportive care pathways.

Full-Path Coordination

From medical record review to post-infusion follow-up, with bilingual support and caregiver arrangements.

Your Treatment Journey in China

A typical BCMA CAR-T pathway takes 8–12 weeks from first consultation to infusion.

Step 1 · Week 1–2

Eligibility Screening

Send your pathology, treatment history, and latest labs. Our clinical team reviews against NMPA indications and trial criteria.

Step 2 · Week 2–3

Hospital Matching & Acceptance

We match you to the best center based on your case, arrange remote consultation, and obtain hospital acceptance letter.

Step 3 · Week 3–5

Visa & Travel

Hospital invitation letter for medical visa, S2 visa for caregiver, flight and accommodation arrangements.

Step 4 · Week 5–9

Apheresis & Cell Manufacturing

T-cell collection (apheresis), CAR-T cell manufacturing (3–4 weeks), and bridging therapy if needed to control disease.

Step 5 · Week 9–10

Lymphodepletion & Infusion

3–5 days of lymphodepletion chemotherapy, then CAR-T cell infusion (Day 0). Short procedure, typically 30–60 minutes.

Step 6 · Week 10–14

Monitoring & Recovery

CRS/ICANS monitoring, blood count recovery, and discharge planning with follow-up schedule coordinated with your home oncologist.

Frequently Asked Questions

Yes. China has NMPA-approved BCMA-directed CAR-T therapies for relapsed/refractory multiple myeloma, including cilta-cel (Carvykti equivalent) and domestic BCMA CAR-T products. Available at designated tertiary hematology centers in Shanghai, Beijing, and Tianjin. Eligibility typically requires ≥3 prior lines (PI + IMiD + anti-CD38).

NMPA-approved commercial BCMA CAR-T typically ranges USD 100,000–250,000 per infusion, excluding hospitalization. Clinical trials may offer the investigational product at no drug cost, with strict eligibility. Unregistered products are not recommended. Quotes below USD 50,000 typically refer to trial enrollment, not approved therapy.

Generally: (1) R/R after ≥3 prior lines including PI (bortezomib), IMiD (lenalidomide), and anti-CD38 (daratumumab); (2) Adequate organ function; (3) ECOG performance status 0–1; (4) No active uncontrolled infection. Some earlier-line trials may accept fewer prior lines. SinoCareBridge submits records for formal hospital screening.

BCMA CAR-T has shown high overall response rates (ORR 70–90%+) in relapsed/refractory myeloma clinical trials. Outcomes vary by prior treatment lines, cytogenetic risk, and disease burden. China's large patient volume means extensive real-world experience. Note: CAR-T is not a guaranteed cure, and some patients may relapse. Discuss expected outcomes with your treating physician.

Yes. International patients can access approved therapies and selected clinical trials. Process: (1) medical record review, (2) hospital acceptance & invitation letter, (3) medical visa + S2 visa for caregiver, (4) treatment & monitoring. Key considerations: language barriers (most ward staff don't speak English), caregiver requirements, and self-pay costs. SinoCareBridge provides end-to-end bilingual coordination.

Autologous stem cell transplant (ASCT) uses the patient's own stem cells to rescue bone marrow after high-dose chemotherapy, typically used earlier in the disease course for eligible patients. CAR-T therapy genetically engineers T cells to target cancer, used for relapsed/refractory disease after multiple prior treatments. They are not mutually exclusive — some patients receive ASCT first, then CAR-T upon relapse. Your physician determines the appropriate sequence.

Last updated: August 2026 · For educational purposes only, not medical advice.

Get Your Free Eligibility Assessment

Send your diagnosis and treatment history. Our clinical team reviews your records and provides a personalized pathway summary — including whether BCMA CAR-T, ASCT, or a clinical trial is the best option — within 24 hours. No obligation.

📧 contact@sinocarebridge.com · 📞 +852 5275 8101

Start Your Regeneration Journey

Stem cell therapy offers new hope for patients seeking natural healing and long-term recovery. Whether your goal is to reverse disease, repair injury, or enhance vitality, our advanced stem cell programs open the door to a healthier, more vibrant future.

Plan Your Stem Cell Therapy Now

CIHA-ACCREDITED HOSPITALS

JCI-ACCREDITED HOSPITALS

GMP-CERTIFIED FACILITIES

ISO CERTIFIED PROCEDURES